FMBA of Russia has received a patent for the drug from COVID-19
Rospatent granted a patent for the drug latrygin developed by researchers of SCIENCE “Science center of biomedical technologies” of FMBA of Russia for treatment and prevention of cytokine storm – a dangerous complications of coronavirus infection.
A “Hexapeptide Tyr-D-Ala-Gly-Phe-Leu-Arg is a fully domestic development. Its uniqueness lies in the fact that it in no way repeats the foreign experience. This is the first and only so far in the world agonist of Delta-opioid receptors, which was released in practical medicine”, – noted in the FMBA of Russia.
As explained in the FMBA, the common name of the original drug dalargin, it was previously used for the treatment of stomach ulcers, acute pancreatitis and pancreatic necrosis. Russian scientists have found that this substance plays an active role in the processes of healing and tissue regeneration, and also takes part in the organization of the immune response. On the basis of dalargin has developed a proprietary drug beitragen.
In Rospatent separately note that latrygin – fully domestic product, he, like all components, can be fully manufactured in Russia. After completion of clinical trials and drug registration in the Ministry of health, Scientific center of biomedical technologies of FMBA of Russia will be able to mass-produce.
